When was ITM founded?

ITM was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Where is ITM located?

ITM is headquartered in Munich, Germany.

How many employees does ITM have?

As of Sep 30, 2026, the latest employee count at ITM is 662.

Is ITM a funded company?

ITM is a funded company, having raised a total of $681M across 9 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jun 01, 2009.

When was the latest funding round of ITM?

ITM's latest funding was a $***** Conventional Debt round on May 27, 2025, with participation from 1 investor.

Where does ITM rank among its competitors?

ITM ranks 87th amongst 2563 active competitors, of which 869 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of ITM?

ITM's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

ITM - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is ITM an acquired company?

ITM got acquired by Telix Pharma on Sep 21, 2026.

Company Details

Developer of radiopharmaceuticals and radioisotopes for cancer treatment. The company's lead product is radionuclide therapy candidate LuCaFab (ITM-31) for the treatment of malignant brain tumors. The company offers medical isotopes like EndolucinBeta and TOCscan. It also offers radiolabelling and quality control equipment like iQS - Theranostics Synthesizer, iQS Ga-68, Fluidic Labeling, Module Reagent Set Manual, and 177Lu Labeling.

Website: www.itm-radiopharma.com/home/
Social
Email ID: *****@itm-radiopharma.com
Phone Number: +49 **********

Key Metrics

Founded Year

2004

Location

Munich, Germany

Stage

Acquired

Total Funding

$681M in 9 rounds

Latest Funding Round

Conventional Debt, May 27, 2025, $*****

Investors

Temasek & 17 more

Ranked

87^th among 2563 active competitors

Employee Count

662 as on Sep 30, 2026

Investment & Acquisitions

Positron Precision

Similar Companies

RayzeBio & 108 more

Exit Details

Acquired by Telix Pharma (Sep 21, 2026)

View ITM's full profile

ITM is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Itm Isotope Technologies Munich Se CIN: HRB269592 , Germany, Active		-	107 (As on Dec 31, 2023)
ITM Isotope Technologies Munich Aktiengesellschaft CIN: HRB154944 , Germany, Active	Dec 01, 2004	-	54 (As on Dec 31, 2021)

ITM got acquired by Telix Pharma on Sep 21, 2026 at an acquisition amount of $*****.

Click here to take a look at ITM's acquisition in detail

ITM has raised a total funding of $681M over 9 rounds. Its first funding round was on Jun 01, 2009. Its latest funding round was a Conventional Debt round on May 27, 2025 for $*****. 1 investor participated in its latest round. ITM has 18 institutional investors.

Here is the list of recent funding rounds of ITM:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 27, 2025	9628365	Conventional Debt	6574535	9957412	6174114	4707310
Jun 06, 2024	9218011	Series E	6551576	4037320	2231960	BlackRock & 3 more
Jun 05, 2023	4483499	Series E	3374042	2010255	Temasek	Nextech Invest & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of ITM's funding rounds and investors

The founders of ITM is Oliver Buck. Steffen Schuster is the CEO of ITM.

Here are the details of ITM's key team members:

Oliver Buck: Founder of ITM.
Steffen Schuster: CEO of ITM.

View details of ITM's Founder profiles and Board Members

ITM's employee count trend

ITM has 662 employees as of Sep 26. Here is ITM's employee count trend over the years:

Uncover ITM's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ITM include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of ITM, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
87th	ITM 2004, Munich (Germany), Acquired	Developer of radiopharmaceuticals and radioisotopes for cancer treatment	$681M	Temasek, Qatar Investment Authority & 16 others	64/100